# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 – 11 years, and only the secon...
Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.
Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that it presented real-world data from US patient surveys that as...
The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 is taking place in Valencia, Spain from May 31-Ju...
HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target f...
Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.